webinar register page

Webinar banner
Ladies, Why Should You Get Screened for Cancer?
This webinar will feature guest speakers and patient advocates to help health care professionals and the Latino public understand the cultural and other barriers to cancer screening and demystify screening tests. Speakers will also share testimonials of getting screened and of Latinas who have gotten screened.

This is the sixth and final webinar of a series, “Let’s Address Health Equity Together.”

The series is a collaboration of the Salud America! program at the Institute for Health Promotion Research at UT Health San Antonio, the Mays Cancer Center at UT Health San Antonio, and Genentech.

Oct 4, 2022 01:00 PM in Central Time (US and Canada)

* Required information
Loading

Speakers

Dr. Amelie G. Ramirez
Cancer Researcher @UT Health San Antonio
Dr. Amelie G. Ramirez is an internationally recognized researcher in Latino health promotion and behavioral change. She is director of Salud America! and its home base, the Institute for Health Promotion Research in the Department of Population Health Sciences at UT Health San Antonio. She has spent over 30 years directing research on human and organizational communication to reduce chronic disease and cancer health disparities affecting Latinos, including cancer risk factors, clinical trial recruitment, tobacco prevention, obesity prevention, and promotion of health equity. She also is associate director of cancer outreach and engagement at the NCI-designated Mays Cancer Center at UT Health San Antonio.
Dr. Marcela Mazo Canola
Cancer Clinician @UT Health San Antonio
Dr. Marcela Mazo Canola is a specialist in hematology/oncology at the NCI-designated Mays Cancer Center at UT Health San Antonio. Dr. Mazo obtained her medical degree from CES University in Medellin, Colombia in 2007. She then attended UT Health San Antonio, where she completed a year of research followed by her internship and residency in internal medicine, then fellowship in hematology/oncology. In 2012, she was awarded Outstanding Resident Medicine Clerkship at the university. Her research interests are solid tumors malignancies in the Latino population, as well as the different health disparities that affect our community. Dr. Mazo has certifications in the American Board of Internal Medicine, Hematology and Medical Oncology.
Debbie Denardi
Cancer Survivor / Patient Advocate
Debbie Denardi was diagnosed with triple-negative breast cancer in 2010. A native of Buenos Aires, Argentina, she was only 48 years old at the time. Due to a family history of multiple cancers, including breast cancer, which took the life of my mother at age 44, my oncologist recommended genetic testing which revealed I was positive for the BRCA1 genetic mutation. After a diagnosis of triple-negative breast cancer, multiple treatments, and surgeries, I am cancer free. I am passionate about encouraging anyone with a family history of cancers to get genetic testing so they can avoid going through what I had to go through. I am volunteer and board member of FORCE (Facing Hereditary Cancer Empowered). I volunteer with many organizations to advance research for hereditary cancer patients. I am also passionate about access to care for our Latinx community. I am a 12-year survivor.
Tania Szado
@Genentech
Dr. Tania Szado is Principal Oncology Medical Science Director, US Medical Affairs, Scientific Collaborations & Alliances, at Genentech. She started with Roche in Basel as a lab head in preclinical toxicology in 2007 before moving to Roche in the UK where she joined the Perjeta clinical development team for four years. After the Roche-Genentech merger, Tania transferred to Genentech in SSF where she worked her way up to Principal Clinical Scientist on the Perjeta team and worked as the safety leader for the Perjeta ODAC. She joined the Oncology Leadership Team in December 2014 where she stayed for the next 5 years as chief of staff to the head of Product Development in Oncology at Roche-Genentech. Tania moved to USMA almost 3 years ago where she led the strategic development of the a tumor agnostic, biomarker driven phase II study in the US community sites and leads the OneOncology partnership in addition to recently joining scientific collaborations where she supports NCI studies.